Literature DB >> 15579180

A new less-invasive and more informative low-dose ACTH test: salivary steroids in response to intramuscular corticotrophin.

Liliana N Contreras1, Alejandro L Arregger, Gabriel G Persi, Natalia S Gonzalez, Estela M Cardoso.   

Abstract

OBJECTIVE: The intravenous low-dose ACTH test has been proposed as a sensitive tool to assess adrenal function through circulating steroids. The aims of this study were to: (a) find the minimal intramuscular ACTH dose that induced serum and salivary cortisol and aldosterone responses equivalent to those obtained after a pharmacological dose of ACTH; and (b) define the minimum normal salivary cortisol and aldosterone responses in healthy subjects to that dose of ACTH. We also compared the performances of the standard- and low-dose ACTH intramuscular tests to screen patients with known hypothalamo-pituitary-adrenal impairments.
DESIGN: Rapid ACTH tests were performed in individuals using various intramuscular doses (12.5, 25 and 250 microg) at 2-week intervals.
SUBJECTS: Twenty-one healthy volunteers and 19 patients with primary (nine cases) and secondary (10 cases) adrenal insufficiency. MEASUREMENT: Serum and salivary cortisol and aldosterone concentrations were measured at baseline and after ACTH. Serum cortisol > or = 552.0 nmol/l and aldosterone > or = 555.0 pmol/l concentrations at 30 min after 250 microg of ACTH were defined as normal responses.
RESULTS: In healthy volunteers cortisol and aldosterone responded to ACTH in a dose-dependent manner. The time to peak in saliva for each steroid was delayed as the dose of ACTH increased. The minimum ACTH dose that produced equivalent steroid responses at 30 min to 250 microg of ACTH (standard-dose test; SDT) was 25 microg (low-dose test; LDT). Saliva collection 30 min after LDT and SDT showed cortisol and aldosterone concentrations of at least 20.0 nmol/l and 100.0 pmol/l, respectively. These values were defined as normal steroid responses. Blunted salivary steroid responses to LDT and SDT were found in all patients with primary adrenal insufficiency. Subnormal salivary cortisol levels in response to LDT and SDT were found in all patients with secondary adrenal insufficiency. In five patients full recovery of adrenal function was demonstrated by both tests after steroid withdrawal. In the follow-up of four patients studied during the recovery period, subnormal SAF response after LDT and normal after SDT was demonstrated. Preservation of the adrenal glomerulosa was found in all the patients with secondary adrenal insufficiency through the normal rise in salivary aldosterone after both LDT and SDT.
CONCLUSIONS: Adrenal function can be accurately investigated with simultaneous measurements of salivary cortisol and aldosterone in response to 25 microg of corticotrophin injected into the deltoid muscle. Our data suggest that this may become a useful and relatively noninvasive clinical tool to detect subclinical hypoadrenal states.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579180     DOI: 10.1111/j.1365-2265.2004.02144.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

1.  Immediate postoperative cortisol levels accurately predict postoperative hypothalamic-pituitary-adrenal axis function after transsphenoidal surgery for pituitary tumors.

Authors:  Nicholas F Marko; Amir H Hamrahian; Robert J Weil
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

2.  Total and free cortisol levels during 1 μg, 25 μg, and 250 μg cosyntropin stimulation tests compared to insulin tolerance test: results of a randomized, prospective, pilot study.

Authors:  Seenia Peechakara; James Bena; Nigel J Clarke; Michael J McPhaul; Richard E Reitz; Robert J Weil; Pablo Recinos; Laurence Kennedy; Amir H Hamrahian
Journal:  Endocrine       Date:  2017-07-20       Impact factor: 3.633

3.  Characterization of the serum and salivary cortisol response to the intravenous 250 µg ACTH1-24 stimulation test.

Authors:  Brendan J Nolan; Jane Sorbello; Nigel Brown; Goce Dimeski; Warrick J Inder
Journal:  Endocrine       Date:  2018-01-03       Impact factor: 3.633

4.  Comparison of salivary and calculated free cortisol levels during low and standard dose of ACTH stimulation tests in healthy volunteers.

Authors:  Gulsah Elbuken; Fatih Tanriverdi; Zuleyha Karaca; Mustafa Kula; Selma Gokahmetoglu; Kursad Unluhizarci; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2014-08-13       Impact factor: 3.633

5.  Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison's disease.

Authors:  K Løvås; T E Thorsen; E S Husebye
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

6.  Analysis of volatile organic compounds in human saliva by a static sorptive extraction method and gas chromatography-mass spectrometry.

Authors:  Helena A Soini; Iveta Klouckova; Donald Wiesler; Elisabeth Oberzaucher; Karl Grammer; Sarah J Dixon; Yun Xu; Richard G Brereton; Dustin J Penn; Milos V Novotny
Journal:  J Chem Ecol       Date:  2010-08-31       Impact factor: 2.626

Review 7.  Secondary hypoadrenalism.

Authors:  Giuseppe Reimondo; Silvia Bovio; Barbara Allasino; Massimo Terzolo; Alberto Angeli
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  [Prevalence of polyglandular autoimmune syndrome in patients with diabetes mellitus type 1].

Authors:  Wilgard Hunger-Battefeld; Katharina Fath; Alexandra Mandecka; Michael Kiehntopf; Christof Kloos; Ulrich Alfons Müller; Gunter Wolf
Journal:  Med Klin (Munich)       Date:  2009-04-01

9.  Salivary cortisol in the diagnosis of adrenal insufficiency: cost efficient and patient friendly.

Authors:  Marloes L P Langelaan; Jérôme M H Kisters; Mirjam M Oosterwerff; Arjen-Kars Boer
Journal:  Endocr Connect       Date:  2018-03-12       Impact factor: 3.335

10.  A novel method for the measurement of glucocorticoids in dermal secretions of amphibians.

Authors:  R M Santymire; M B Manjerovic; A Sacerdote-Velat
Journal:  Conserv Physiol       Date:  2018-02-16       Impact factor: 3.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.